Advertisement

Journal of Neurology

, Volume 255, Issue 9, pp 1378–1383 | Cite as

Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS

A large scale, short-term follow-up study
  • S. Mesaros
  • M. A. Rocca
  • M. P. Sormani
  • A. Charil
  • G. Comi
  • M. FilippiEmail author
ORIGINAL COMMUNICATION

Abstract

To assess the value of clinical and MRI variables in predicting short-term brain atrophy accumulation and clinical evolution in a large cohort of patients with RRMS, we studied a cohort of 548 patients, previously enrolled as a placebo arm of a 14-month, double-blind trial of oral glatiramer acetate (GA). A logistic regression model with EDSS progression as the dependent variable was built to assess baseline clinical and MRI variables associated with clinical worsening during follow-up. In 466 patients with complete central brain atrophy assessment, another linear regression model with percentage central brain volume change (PCBVC) as the dependent variable was built to assess baseline clinical and MRI variables associated with atrophy development.

A total of 80 patients (15 %) had EDSS progression over the follow-up period. Factors independently predicting the probability to have a clinical progression were lower EDSS (OR = 0.78, 95 % CI = 0.62–0.97 p = 0.02) and higher T2 LL (OR = 1.022, 95 % CI = 1.006–1.038, p = 0.007) at baseline. In the 466 patients with atrophy assessment, PCBVC declined, on average, by –2.0 % (SD = 2.8) (p < 0.001) over the follow-up. The multivariate PCBVC analysis revealed that the PCBVC decrease was independently correlated with higher EDSS (p = 0.03) and T2 LL (p = 0.005) at baseline. The squared correlation coefficients of the composite scores made up of EDSS and T2 LL considered together were able to explain only 3 % of the variance in disability progression and only 4 % of the variance of PCBVC.

In RRMS patients, clinical and conventional MRI findings at baseline only modestly predict shortterm accumulation of brain atrophy and disability. These data confirm the need to develop clinical and MRI measures more sensitive towards the more disabling aspects of the disease.

Key words

multiple sclerosis disability conventional MRI brain atrophy disease evolution 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M (2006) Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 129:2620–2627PubMedCrossRefGoogle Scholar
  2. 2.
    Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N (2004) Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 63:89–93PubMedGoogle Scholar
  3. 3.
    Belinda SY, Regal J, Soher BJ, Mannon LJ, Grossman RI, Gonen O (2003) Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 24:68–74Google Scholar
  4. 4.
    Brex PA, Ciccareli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158–164PubMedCrossRefGoogle Scholar
  5. 5.
    Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldman H, Compston DA (2006) The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 253:2059–2069CrossRefGoogle Scholar
  6. 6.
    De Stefano N, Filippi M (2007) MR Spectroscopy in multiple sclerosis. J Neuroimaging 17:31S–35SPubMedCrossRefGoogle Scholar
  7. 7.
    Fazekas F, Soelberg-Sorensen P, Comi G, Filippi M (2007) MRI to monitor treatment efficacy in multiple sclerosis. J Neuroimaging 17:50S–55SPubMedGoogle Scholar
  8. 8.
    Filippi M, Horsfield MA, Ader HJ, Barkhof F, Bruzzi P, Evans A, Frank JA, Grossman RI, McFarland HF, Molyneux P, Paty DW, Simon J, Tofts PS, Wolinsky JS, Miller DH (1998) Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 43:499–506PubMedCrossRefGoogle Scholar
  9. 9.
    Filippi M, Horsfield MA, Morrissey SP, Rudge P, McDonald WI, Miller DH (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635–641PubMedGoogle Scholar
  10. 10.
    Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH (1995) Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 45:255–260PubMedGoogle Scholar
  11. 11.
    Filippi M, Rocca MA (2007) Conventional MRI in multiple sclerosis. J Neuroimaging 17:3S–9SPubMedGoogle Scholar
  12. 12.
    Filippi M, Wolinsky JS, Comi G, the CORAL Study Group (2006) Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 5:213–220PubMedCrossRefGoogle Scholar
  13. 13.
    Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee J-C, Miller D, Weinstock- Guttman B, Mass MK, Dougherty DS, Simonian NA (2002) Eightyear follow-up study of brain atrophy in patients with MS. Neurology 59:1412–1420PubMedGoogle Scholar
  14. 14.
    Gauthier SA, Mandel M, Guttmann CRG, Glanz BI, Khoury SJ, Betensky RA, Weiner HL (2007) Predicting short-term disability in multiple sclerosis. Neurology 68:2059–2065PubMedCrossRefGoogle Scholar
  15. 15.
    Horsfield MA (2005) Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 15:58S–67SPubMedCrossRefGoogle Scholar
  16. 16.
    Jasperse B, Minneboo A, de Groot V, Kalkers NF, van Helden PE, Uitdehaag BMJ, Barkhof F, Polman CH (2007) Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Arch Neurol 64:190–194PubMedCrossRefGoogle Scholar
  17. 17.
    Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F (2002) Longitudinal brain volume measurement in multiple sclerosis. Rate of brain atrophy is independent of disease subtype. Arch Neurol 59:1572–1576PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan MR, Meyer-Franke A, Lambert S, Bennet V, Duncan ID, Levinson SR, Barres BA (1997) Induction of sodium channel clustering by oligodendrocytes. Nature 386:724–728PubMedCrossRefGoogle Scholar
  19. 19.
    Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CRG, Weiner HL, Gasperini C, Filippi M for the Gadolinium MRI Meta-analysis Group (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 353:964–969PubMedCrossRefGoogle Scholar
  20. 20.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  21. 21.
    Li DK, Paty DW and the UBC MS/MRI Analysis Research group and the PRISMS Study Group (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, doubleblind, placebo-controlled study of interferon- beta 1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferonbeta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 46:197–206PubMedCrossRefGoogle Scholar
  22. 22.
    Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009–2019PubMedCrossRefGoogle Scholar
  23. 23.
    Miki Y, Grossman RI, Udupa JK, Wei L, Polansky M, Mannon LJ, Kolson DL (1999) Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images-lack of correlation between changes in T2 lesion volume and clinical findings. Radiology 213:395–399PubMedGoogle Scholar
  24. 24.
    Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676–1695PubMedCrossRefGoogle Scholar
  25. 25.
    Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH for the European Study Group on Interferon Beta-1b in Secondary Progressive MS (2000) The effect of interferon beta 1-b treatment on MRI measures in secondary progressive multiple sclerosis. Brain 123:2256–2263PubMedCrossRefGoogle Scholar
  26. 26.
    Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner k, Yousry T, Miller DH for the European Study Group on Interferon Beta-1b in Secondary Progressive MS (2001) Clinical-MRI correlations in European trial of interferon-beta 1b in secondary progressive MS. Neurology 57:2191–2197PubMedGoogle Scholar
  27. 27.
    Pagani E, Bammer R, Horsfield MA, Rovaris M, Gass A. Ciccarelli O, Filippi M (2007) Diffusion MR imaging in multiple sclerosis: technical aspects and challenges. AJNR Am J Neuroradiol 28:411–420PubMedGoogle Scholar
  28. 28.
    Pfrieger FW, Barres BA (1997) Synaptic efficacy enhanced by glial cells in vitro. Science 277:1684–1687PubMedCrossRefGoogle Scholar
  29. 29.
    Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G, Filippi M (2003) Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 126:2323–2332PubMedCrossRefGoogle Scholar
  30. 30.
    Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E, Weiss S, Shifroni G, Wolinsky JS, Filippi M, for the European/Canadian Glatiramer Acetate Study Group (2007) Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/ Canadian double-blind, placebocontrolled, MRI-monitored trial. Mult Scler 13:502–508PubMedGoogle Scholar
  31. 31.
    Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M and the European/ Canadian Glatiramer Acetate Study Group (2001) Short term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 124:1803–1812PubMedCrossRefGoogle Scholar
  32. 32.
    Rovaris M, Inglese M, van Schijndel RA, Sormani MP, Rodegher M, Comi G, Filippi M (2000) Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol 247:960–965PubMedCrossRefGoogle Scholar
  33. 33.
    Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA (2001) Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 56:1324–1330PubMedGoogle Scholar
  34. 34.
    Rudick RA, Fisher E, Lee J-C, Duda JT, Simon J (2000) Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a. Mult Scler 6:365–372PubMedGoogle Scholar
  35. 35.
    Rudick RA, Lee J-C, Simon J, Fisher E (2006) Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 60:236–242PubMedCrossRefGoogle Scholar
  36. 36.
    Sailer M, Lossef NA, Wang L, Gawne- Cain ML, Thompson AJ, Miller DH (2001) T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis: a prospective 18 month followup study. Eur J Neurol 8:37–42PubMedCrossRefGoogle Scholar
  37. 37.
    Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE III, Brownscheidle CM (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 53:139–148PubMedGoogle Scholar
  38. 38.
    Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, Rashid W, Sastre-Garriga J, Thompson AJ, Miller DH (2005) Gray and white matter volume changes in early RRMS. A 2- year longitudinal study. Neurology 64:1001–1007PubMedGoogle Scholar
  39. 39.
    Tortorella C, Viti B, Bozzali M, Sormani MP, Rizzo G, Gilardi MF, Comi G, Filippi M (2000) A magnetization transfer histogram study of normalappearing brain tissue in MS. Neurology 54:186–193PubMedCrossRefGoogle Scholar
  40. 40.
    Trapp BD, Ranshoff R, Fusher E, Rudick RA (1999) Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5:48–57CrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • S. Mesaros
    • 1
  • M. A. Rocca
    • 1
    • 2
  • M. P. Sormani
    • 1
    • 3
  • A. Charil
    • 1
  • G. Comi
    • 2
  • M. Filippi
    • 1
    • 2
    Email author
  1. 1.Neuroimaging Research UnitScientific Institute and University H San RaffaeleMilanItaly
  2. 2.Dept. of NeurologyScientific Institute and University Ospedale, San RaffaeleMilanItaly
  3. 3.Unit of Biostatistics, DISSALUniversity of GenoaGenoaItaly

Personalised recommendations